Survodutide may treat liver disease by addressing the underlying metabolic problems that cause fatty liver, such as excess body fat, insulin resistance, and inflammation
From traditional injections to pills, GLP-1s are being made more accessible to different types of consumers
During the development of nonalcoholic fatty liver disease (NAFLD), disorders of the carnitine pool are considered important drivers, in which the LCAC profile changes significantly with the progression of NAFLD and provides key clues for revealing the complex pathogenesis of NAFLD [209, 210]
While ongoing monitoring of calcitonin during GLP-1 therapy is not standard practice, patients should receive education about thyroid cancer warning signs and the importance of reporting new symptoms
Treatments are safe, non-invasive, and tailored to individual needs following a naturopathic and functional medicine assessment
Nature Metabolism, 6 (3), 433